Adding PD-(L)1 inhibitors to chemotherapy improved outcomes, but PD-(L)1 inhibitors alone were no more effective than chemotherapy alone in patients with gastric, gastroesophageal junction, and ...

Treatment with ¹⁷⁷Lu-PSMA-617 appears more effective than changing ARPIs for patients with mCRPC whose disease progressed on a prior ARPI.

Trimodal therapy may be an effective alternative to radical cystectomy for recurrent, high-grade T1 bladder cancer, according to a study published in the Journal of Clinical Oncology.

(HealthDay News) — Axatilimab produces responses in patients with recurrent or refractory graft-vs-host disease (GVHD), according to a study published in The New England Journal of Medicine.

Americans have the worst health care among the world’s wealthy nations, according to a report from health care think-tank The Commonwealth Fund. The report showed that people in the United States die ...

A large study suggests that pediatric cancer patients are more likely to die in the hospital than at home. The data showed that 52% of patients died in the hospital, and 40% died at home. These ...

SBRT and hypofractionated CRT produced similar outcomes in patients with inoperable stage I NSCLC in a phase 3 trial.

The FDA has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible, newly diagnosed multiple myeloma.

Implementing weighted-average drug pricing in the United States could reduce the cost of cancer drugs, data suggest.

A novel CAR T-cell therapy, GCC19CART, has demonstrated activity in patients with heavily pretreated, metastatic colorectal cancer.

(HealthDay News) — Among cancer survivors, excess body weight is associated with an increased risk of a second primary cancer, according to a study published in JAMA Network Open.

Credit: Science Source images Cabozantinib plus atezolizumab “may be useful” for selected patients with mCRPC whose disease progressed on hormone therapy, according to Neeraj Agarwal, MD.